

CELL THERAPEUTICS INC  
Form 8-K  
February 02, 2007

---

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

### FORM 8-K

---

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) February 2, 2007

---

## Cell Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Washington  
(State or other jurisdiction

of incorporation)

001-12465  
(Commission File No.)

91-1533912  
(I.R.S. Employer

Identification No.)

501 Elliott Avenue West, Suite 400

Seattle, Washington 98119

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: 206-282-7100

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

## Edgar Filing: CELL THERAPEUTICS INC - Form 8-K

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 3.03 Material Modification to Rights of Security Holders.**

On February 2, 2007, the Company filed an amendment to its Articles of Incorporation establishing a one-for-four reverse stock split, effective at the close of business Pacific Time on April 2, 2007.

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year**

On February 2, 2007, the Company filed an amendment to its Articles of Incorporation establishing a one-for-four reverse stock split, effective at the close of business Pacific Time on April 2, 2007.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits. The following exhibits are included in this report:

99.1 Amendment to Articles of Incorporation..

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**CELL THERAPEUTICS, INC.**

Date: February 2, 2007

By: /s/ Louis A. Bianco  
Louis A. Bianco  
Executive Vice President, Finance and Administration